Multiple Sclerosis

Multiple sclerosis (MS) is a condition of the central nervous system, where there is interference in the nerve impulses within the brain, spinal cord and optic nerves. Scars occur within the central nervous system and, depending on where they develop, manifest into various symptoms such as problems with motor control (muscle spasms, weakness, lack of coordination/balance and functioning of arms and legs) neuropsychological issues (memory loss and cognitive issues), bladder and bowel incontinence, and other neurological symptoms such as vertigo, pins and needles, neuralgia and visual disturbances. Fatigue is among the most commonly reported, most disabling but least understood symptom experienced by patients with MS. Patients differ in the symptoms they experience depending on where lesions have developed on the brain and spinal cord. MS affects over 25,600 of the Australia population. The burden of disease on the patient and their family/carers is high and the economic effect on the health system and wider economy is substantial.

N-of-1 methods

There is currently no known cure for MS however there are numerous treatment options available to help manage symptoms and slow progression of the disease. The gold standard research design for testing treatments is the ‘randomised controlled trial’ (RCT). However, RCTs identify whether a treatment is effective for patients on average and provide less information about whether a treatment is effective for each individual patient in the trial. N-of-1 methods can be used to evaluate how individual patients respond to treatments and to understand how symptoms fluctuate over time, which may help self-management of the condition.

Why do the study?

The current research study uses N-of-1 methods to explore patterns and predictors of MS symptoms over time and provide personalised feedback about these data to participants. The information provided during the study will help to inform approaches for the management of symptoms and for future research using similar research methods to test treatments and interventions. The study has received ethical approval from the UQ Medical Faculty ethics committee.

Participating in the study

To be eligible for this study people must have a medical diagnosis of MS and be willing to complete brief questionnaires on a daily basis for 6 weeks.

To read more about this study please read the participant information sheet.


Contact the lead researcher, Dr Suzanne McDonald, by email at or phone on 0490 936 307.